Opinion|Videos|March 11, 2025
Optimizing Treatment Sequencing in Advanced Colorectal Cancer
Experts discuss additional factors considered when determining the most effective sequence of therapies for metastatic colorectal cancer, including fruquintinib, regorafenib, and trifluridine + tipiracil ± bevacizumab, and explore the further research needed to understand optimal sequencing of these treatments better.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What additional factors do you consider when determining the most effective sequence of these therapies (fruquintinib, regorafenib, trifluridine + tipiracil ± bevacizumab)?
- What further research is needed to understand optimal sequencing of these therapies better?
Advertisement
Related to this article
Longer undetectable hepatitis D RNA on bulevirtide predicts durable suppression off therapy, but rebound and ALT flares rise, especially in cirrhosis.
Experts tackled CAR T access, trial equity, and overtreatment in breast cancer at an AJMC Institute for Value-Based Medicine event in San Francisco.
Systematic review finds combined immunonutrition (arginine, omega-3s, glutamine) in colorectal cancer surgery may cut surgical site infections, while single supplements show no benefit.
FACT Accreditation lets Tennessee Oncology bring community oncology CAR T-cell therapy closer to home, expanding access for non-Hodgkin lymphoma patients.
The analysis found a nonlinear association between systemic inflammation and overactive bladder, with stronger links at higher inflammation levels.
A real-world study found that adding a GLP-1 to SGLT2 inhibitor therapy was associated with lower kidney, cardiovascular, and mortality risks in CKD.
In experiments at MD Anderson, rising CD70 helps mantle cell lymphoma evade immunity; a CD70×CD3 bispecific restores T-cell killing and prolongs survival in resistant models.
The NPS index, ranging from –100 to +100, serves as a proxy for customers’ willingness to recommend products and services they themselves have used.
Advertisement
Advertisement
Trending on AJMC
1
Medicare Cap Eases Patient Costs as Negotiation Squeezes Practices
2
Access and Innovation in North Carolina’s Research Triangle
3
Biomarker-Driven Care Is Racing Ahead of the Systems Built to Support It
4
Overcoming Barriers to Precision Care and Patient Access
5